ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,775 | -47.8% | 696 | 0.0% | 0.00% | -42.9% |
| Q2 2023 | $14,895 | -47.1% | 696 | 0.0% | 0.01% | -50.0% |
| Q1 2023 | $28,147 | -13.1% | 696 | 0.0% | 0.01% | -17.6% |
| Q4 2022 | $32,378 | -10.1% | 696 | 0.0% | 0.02% | -10.5% |
| Q3 2022 | $36,000 | +9.1% | 696 | 0.0% | 0.02% | +11.8% |
| Q2 2022 | $33,000 | -34.0% | 696 | 0.0% | 0.02% | -26.1% |
| Q1 2022 | $50,000 | -3.8% | 696 | 0.0% | 0.02% | 0.0% |
| Q4 2021 | $52,000 | +30.0% | 696 | 0.0% | 0.02% | +15.0% |
| Q3 2021 | $40,000 | +29.0% | 696 | 0.0% | 0.02% | +25.0% |
| Q2 2021 | $31,000 | -8.8% | 696 | 0.0% | 0.02% | -15.8% |
| Q1 2021 | $34,000 | +17.2% | 696 | 0.0% | 0.02% | +11.8% |
| Q4 2020 | $29,000 | -9.4% | 696 | 0.0% | 0.02% | -19.0% |
| Q3 2020 | $32,000 | -8.6% | 696 | 0.0% | 0.02% | -19.2% |
| Q2 2020 | $35,000 | -2.8% | 696 | 0.0% | 0.03% | -18.8% |
| Q1 2020 | $36,000 | -16.3% | 696 | 0.0% | 0.03% | +3.2% |
| Q4 2019 | $43,000 | – | 696 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 1,055,719 | $35,367,000 | 12.68% |
| GREAT POINT PARTNERS LLC | 828,253 | $27,746,000 | 5.70% |
| McClain Value Management LLC | 116,153 | $3,891,000 | 4.80% |
| Stonepine Capital Management, LLC | 231,913 | $7,769,000 | 4.63% |
| ARMISTICE CAPITAL, LLC | 228,000 | $7,638,000 | 1.81% |
| Opaleye Management Inc. | 90,000 | $3,015,000 | 1.78% |
| Matarin Capital Management, LLC | 257,268 | $8,618,478,000 | 0.97% |
| HAYS ADVISORY LLC | 116,939 | $3,917,000 | 0.87% |
| Granahan Investment Management | 496,025 | $16,617,000 | 0.57% |
| AlphaMark Advisors, LLC | 33,000 | $1,106,000 | 0.57% |